Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals Inc (NQ: PHAT )

8.890 +0.110 (+1.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
81 Biggest Movers From Yesterday
Gainers Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Phathom Pharmaceuticals: Q1 Earnings Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
90 Biggest Movers From Yesterday
Gainers 
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shar... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Medigus (NASDAQ:MDGS) shares moved upwards by 12.04% to $1.62 during Thursday's pre-market session. The market value of their outstanding shares is at $38.6... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
30 Stocks Moving in Thursday's Pre-Market Session
Gainers InflaRx N.V. (NASDAQ: IFRX) rose 47.9% to $4.23 in pre-market trading. Raymond James upgraded InflaRx from Outperform to Strong Buy and announced a $14 price target.... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (... 
Via Benzinga
Phathom Pharma's Vonoprazan Inhibits Gastric Acid In Healthy Volunteers
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has reported results from the VONO-103 Phase 1 trial of vonoprazan in healthy subjects. The trial evaluated the effects of... 
Via Benzinga
Director Of Phathom Pharmaceuticals Makes $587 Thousand Sale
David A Socks, Director at Phathom Pharmaceuticals (NASDAQ:PHAT), made a large insider sell on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021
Upgrades Craig-Hallum upgraded the previous rating for ShotSpotter Inc (NASDAQ:SSTI) from Hold to Buy. For the first quarter, ShotSpotter had an EPS of $0.02, compared to... 
Via Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.